News

Pulmonology Advisor1d
ACIP Recommends RSV Vaccine for 50 to 59-Year-Olds at High Risk
ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.
CIDRAP1h
HHS, NIH announce universal vaccine platform, promote placebo trials for new vaccines
The Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) today announced a ...
Recreating the respiratory tract in a dish: Modeling viral infections and testing treatments
A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...
Pharmabiz12d
ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease
the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...
CIDRAP8d
Mouse study suggests prolonged post-mortem SARS-CoV-2 infectivity
The highest risk of transmission of SARS-CoV-2 was in the first 72 hours at room temperature and first 24 hours at 37℃.